SHR-A1811 (Not yet branded)
Other Medications
Description
SHR-A1811 is an antibody-drug conjugate specifically designed to target HER2-expressing colorectal cancers. This therapy is used in patients with advanced colorectal cancer who have failed standard treatments including oxaliplatin and 5-fluorouracil-based regimens. The drug combines a HER2-targeting antibody with a cytotoxic payload to deliver chemotherapy directly to HER2-positive cancer cells.
Mechanism of Action
SHR-A1811 binds specifically to the HER2 receptor protein overexpressed on certain colorectal cancer cells. Upon binding, the conjugate is internalized by the cancer cell, where the cytotoxic payload is released to induce cell death while minimizing damage to normal cells that do not express HER2.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 Estado EMA | Experimental |
 Acceso España | med_spain_not_available |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.